Geron Corporation (GERN)
Symbol Info
Listed Symbol GERN
Name Geron Corporation
Share Info
Annual Info
Latest Fiscal Dividend Per Share $-
Latest Fiscal Date 2018-12-31
Latest Fiscal Revenue $1,066,000
Latest Fiscal EPS $-0.15
Price Info
21 Day Moving Average $1.4195
21 Day EMA $1.421050
50 Day Moving Average $1.3218
50 Day EMA $1.389880
200 Day EMA $1.661420
200 Day Moving Average 1.441260
52 Week High $6.66
52 Week Low $0.95
52 Week Change $-71.908100
Alpha 0.005654
Beta 2.5288
Standard Deviation 0.238809
R2 0.133285
Periods 60
Share Information
10 Day Average Volume 1,619,752
20 Day Average Volume 1,280,977
30 Day Average Volume 1,374,873
50 Day Average Volume 1,477,743
Outstanding Shares 188,423,106
Float Shares 183,516,849
Percent Float 97.40%
Short Interest -
Short Percent Float -
Short Interest Ratio -
Short Date
Holders
Institutions 229
Institute Holdings Date 2019-08-31
Institute Bought Previous 3 Months 2,986,044
Institute Holdings Percent 54.000000
Institute Sold Previous 3 Months 12,013,601
Insider Holdings Date
Insider Bought Previous 3 Months -
Insider Holdings Percent -
Insider Sold Previous 3 Months -
Insiders Shares Owned 4,906,257
Price Change
7 Day Price Change $0.1900001
7 Day Percent Change 13.57%
21 Day Price Change $0.2300000
21 Day Percent Change 16.91%
30 Day Price Change $0.2700000
30 Day Percent Change 20.45%
Month To Date Price Change $0.1900
Month To Date Percent 13.57%
90 Day Price Change $0.120000
90 Day Percent Change 8.16%
Quarter To Date $0.180000
Quarter To Date Percent 12.77%
180 Day Price Change $-0.05
180 Day Percent Change -3.05%
200 Day Price Change $0.070000
200 Day Percent Change 4.61%
Year To Date $0.590000
Year To Date Percent 59.00%
Profile
Description Geron Corp is a clinical stage biopharmaceutical company. Its focus is the development of a telomerase inhibitor, imetelstat, in hematologic myeloid malignancies. Imelstat is expected to directly obstruct malignant-cell proliferation. The company has an exclusive collaboration and license agreement with Janssen Biotech to develop and commercialize imetelstat worldwide for oncology and other human therapeutic uses.
Details
Issue Type CS
Market Cap $299,592,739
Sec Type EQS
Auditor Ernst & Young LLP
Total Shares Outstanding 188,423,106
CEO John A. Scarlett
Employees 18
Last Audit UE
Classification
CIK 0000886744
Industry Biotechnology
Sector Healthcare
NAICS Pharmaceutical Preparation Manufacturing(325412)
Info
Address 149 Commonwealth Drive
Suite 2070
Menlo Park, CA 94025
Website https://www.geron.com
Facisimile +1 650 473-7750
Telephone +1 650 473-7700
Email investor@geron.com
Key Ratios
Profitability
EBIT Margin -6,148.9
EBITDA Margin -6,141.1
Pre-Tax Profit Margin -1,745.7
Profit Margin Cont -
Gross Margin -
Profit Margin TOT -
Income Statements
Revenue $698,000
Revenue Per Share $0.0037
Revenue 3 Years $-61.41
Revenue 5 Years $-21.2
Valuation Measures
PE Ratio -
Enterprise Value $145,622,507
Price To Sales 429.215970
Price To Free Cash -9.7
PE High Last 5 Years -
Price To Book 1.9
Price To Cash Flow 41.1
PE Low Last 5 Years -
Price To Tangible Book 1.9
Financial Strength
Total Debt To Equity -
Int Coverage -
Current Ratio 16.9
Leverage Ratio 1.0
Quick Ratio 16.7
Long Term Debt To Capital -
Assets
Receivables Turnover 0.4
Invoice Turnover -
Assets Turnover -
Management Effectiveness
Return Assets -21.29
Return On Equity -22.18
Return On Capital -24.78
Dividends
Dividend 3 Years $-
Dividend 5 Years $-
Ex Dividend Date
Dividend Rate $-
Dividend Yield -
Payment Type


Your Recent History
NASDAQ
GERN
Geron
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.


NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.